Quick Answer
Jazz Pharmaceuticals plc reported R&D Expense of $299.73 million for fiscal year 2019.
Jazz Pharmaceuticals plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2019 | $299.73M | +32.3% |
| 2018 | $226.62M | +14.2% |
| 2017 | $198.44M | +22.3% |
| 2016 | $162.30M | +20.0% |
| 2015 | $135.25M | +58.8% |
| 2014 | $85.18M | +104.6% |
| 2013 | $41.63M | +103.3% |
| 2012 | $20.48M | +45.0% |
| 2011 | $14.12M | -44.9% |
| 2010 | $25.61M | -29.9% |
| 2009 | $36.56M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2019 | $79.86M | +56.1% | +28.0% |
| June 30, 2019 | $62.38M | +11.1% | +3.8% |
| March 31, 2019 | $60.10M | -4.1% | +17.5% |
| September 30, 2018 | $51.16M | +8.0% | -8.9% |
| June 30, 2018 | $56.13M | +39.8% | -10.4% |
| March 31, 2018 | $62.67M | +39.5% | +32.3% |
| September 30, 2017 | $47.36M | -0.9% | +17.9% |
| June 30, 2017 | $40.16M | +2.7% | -10.6% |
- Jazz Pharmaceuticals plc showed an increase of +32.3% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2019 period, Jazz Pharmaceuticals plc’s r&d expense has grown by 719.8% (from $36.56 million to $299.73 million).
- The most recent figure is from Jazz Pharmaceuticals plc’s fiscal year 2019 report (Form 10-K), filed with the SEC on February 25, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: